Therapies against incurable and metastatic cancers.

Frédéric Caroff
Martine Caroff

Elaia Team

Florian Denis

Related articles

HEPHAISTOS-Pharma, a biotechnology company developing next generation immunotherapies against cancer targeting innate immunity to increase the cure rate of patients, has completed its €4.5 million seed round to finance industrialization and advance its lead candidate ONCO-Boost towards the clinic. Elaia leads a consortium previously initiated by xista science ventures, the Fondation Fournier-Majoie and Noshaq.

2024.05.16 / 3min read.